| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/1756-185X.12154 |
| P698 | PubMed publication ID | 24164839 |
| P50 | author | Sang-Cheol Bae | Q50911059 |
| P2093 | author name string | Young Ho Lee | |
| Gwan Gyu Song | |||
| P2860 | cites work | Hepatitis B virus infection--natural history and clinical consequences | Q29617961 |
| American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. | Q34782898 | ||
| Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach | Q36566911 | ||
| Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy | Q36694864 | ||
| The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature | Q37306090 | ||
| Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients | Q37416404 | ||
| Hepatitis B and C infection in international travelers | Q38098235 | ||
| Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. | Q43062340 | ||
| Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy | Q43268379 | ||
| Anti-TNF-alpha therapy for rheumatoid arthritis among patients with chronic hepatitis B infection | Q44392585 | ||
| Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: a retrospective analysis of 49 cases | Q45359495 | ||
| Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan | Q45361805 | ||
| Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases | Q45362101 | ||
| Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts | Q45369749 | ||
| Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs | Q46162379 | ||
| Rheumatoid arthritis | Q56656479 | ||
| HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines | Q57079502 | ||
| P433 | issue | 5 | |
| P921 | main subject | rheumatism | Q684924 |
| Hepatitis B virus | Q6844 | ||
| hepatitis B | Q6853 | ||
| P304 | page(s) | 527-531 | |
| P577 | publication date | 2013-10-01 | |
| P1433 | published in | International Journal of Rheumatic Diseases | Q15764244 |
| P1476 | title | Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs | |
| P478 | volume | 16 |
| Q30391932 | Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. |
| Q47098502 | Biological therapy in arthritis patients with hepatitis B or C infection: a multicenter retrospective case series |
| Q45324587 | Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive Therapy |
| Q92670104 | Controversies in hepatitis C therapy: Reactivation of hepatitis B virus |
| Q30487002 | Current hepatitis B treatment guidelines and future research directions |
| Q38283963 | Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections |
| Q26773684 | Hepatic manifestations of non-steroidal inflammatory bowel disease therapy |
| Q28076703 | Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-Screened |
| Q38408897 | Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy |
| Q26784247 | Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations |
| Q59360015 | Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians |
| Q42764680 | Immunosuppression in Patients with Chronic Hepatitis B. |
| Q38335718 | Infection risk associated with anti-TNF-α agents: a review |
| Q64897844 | KASL clinical practice guidelines for management of chronic hepatitis B. |
| Q26752475 | KASL clinical practice guidelines: management of chronic hepatitis B |
| Q35664183 | Management of chronic hepatitis B in patients from special populations |
| Q26752690 | Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations |
| Q28078157 | Management of psoriasis patients with hepatitis B or hepatitis C virus infection |
| Q89686417 | Moderate Risk of Hepatitis B Virus Reactivation in HBsAg-/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis |
| Q40830395 | Prevention of HBV reactivation in patients treated with biologic agents. |
| Q26747023 | Prevention of Hepatitis B reactivation in the setting of immunosuppression |
| Q90101823 | Rheumatologists' awareness of hepatitis B reactivation before immunosuppressive therapy |
| Q38611674 | Risk of Hepatitis B Reactivation in Inflammatory Arthritis Patients Receiving Disease Modifying Anti-Rheumatic Drugs (DMARDs): a Systematic Review and Meta-analysis |
| Q35237316 | Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. |
| Q35809610 | Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study |
| Q38261127 | Side-effects of anti-inflammatory therapy in uveitis. |
| Q40695032 | Tacrolimus successfully used to control refractory eosinophilic granulomatosis with polyangiitis complicated by invasive aspergillosis and chronic hepatitis B. |
| Q92128110 | The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19 |
| Q40950014 | The safety and effectiveness of HBV vaccination in patients with juvenile idiopathic arthritis controlled by treatment |
| Q92627208 | The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus |
| Q47546977 | Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice |
| Q50190669 | Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance |
Search more.